Salim Syed
Stock Analyst at Mizuho
(2.13)
# 1,167
Out of 4,667 analysts
71
Total ratings
36.54%
Success rate
-1.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $85.96 | +89.62% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $10.68 | +68.54% | 4 | Aug 16, 2024 | |
| BIIB Biogen | Maintains: Outperform | $277 → $251 | $156.00 | +60.90% | 14 | Aug 6, 2024 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $19 | $14.26 | +33.24% | 4 | Jun 25, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $287.87 | -18.37% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $25.43 | +33.70% | 1 | Apr 9, 2024 | |
| NKTX Nkarta | Maintains: Buy | $31 → $25 | $2.50 | +900.00% | 6 | Mar 22, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $103 → $99 | $49.86 | +98.56% | 5 | Mar 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $47.26 | +109.48% | 3 | Mar 6, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $53 | $23.04 | +130.03% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $90 | $88.63 | +1.55% | 5 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.17 | +412.82% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.10 | +1,809.09% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $15.02 | +139.68% | 1 | Nov 16, 2022 |
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $85.96
Upside: +89.62%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $10.68
Upside: +68.54%
Biogen
Aug 6, 2024
Maintains: Outperform
Price Target: $277 → $251
Current: $156.00
Upside: +60.90%
Wave Life Sciences
Jun 25, 2024
Reiterates: Outperform
Price Target: $19
Current: $14.26
Upside: +33.24%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $287.87
Upside: -18.37%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $25.43
Upside: +33.70%
Nkarta
Mar 22, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $2.50
Upside: +900.00%
Cytokinetics
Mar 6, 2024
Maintains: Buy
Price Target: $103 → $99
Current: $49.86
Upside: +98.56%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $47.26
Upside: +109.48%
BridgeBio Pharma
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $23.04
Upside: +130.03%
Feb 22, 2024
Maintains: Buy
Price Target: $101 → $90
Current: $88.63
Upside: +1.55%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.17
Upside: +412.82%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.10
Upside: +1,809.09%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $15.02
Upside: +139.68%